doi:10.1097/cm9.0000000000000706 Zhu S, Jiang Y, Xu K, et al
GLP-1R Lowers blood glucose by binding to GLP-1, mainly by stimulating insulin secretion and inhibiting glucagon secretion (Drucker, 2018)
In a statement to Insider, Novo Nordisk, the company that makes Wegovy and Ozempic, said that Gila monsters and the discovery of exendin-4 "did not have anything to do with our decision to develop long-acting GLP-1 receptor agonists" for obesity, because "that was based on GLP-1 biology in humans." But the company also said that "the GLP-1-like effect of exendin-4" in Gila monsters was "an important contribution to the field," as it led to the development of the very first injectable drug of its kind
GLP-1 Market Overview 2026 | Size, Share & Industry Trend 2034 REPORT DETAILS GLP-1 Market Summary The global GLP-1 market size was valued at USD 52.82 billion in 2025, growing at a CAGR of 10.9% during 20262034
Non-Hormonal : No PCT needed, safe for continuous use
Targeting toll-like receptors against cancer